Edition:
United Kingdom

Zymeworks Inc (ZYME.TO)

ZYME.TO on Toronto Stock Exchange

16.71CAD
7:10pm GMT
Change (% chg)

$-2.16 (-11.45%)
Prev Close
$18.87
Open
$18.72
Day's High
$18.72
Day's Low
$16.70
Volume
17,580
Avg. Vol
5,938
52-wk High
$30.36
52-wk Low
$9.37

Latest Key Developments (Source: Significant Developments)

Zymeworks files for mixed shelf of up to $250 million - SEC Filing
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Zymeworks Inc ::ZYMEWORKS FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING.  Full Article

Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Beigene Ltd <6160.HK>::ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND LICENSE AGREEMENT FOR ZYMEWORKS’ AZYMETRIC™ AND EFECT™ PLATFORMS GLOBALLY.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE TOTAL UPFRONT PAYMENTS OF US$40 MILLION UNDER ZW25 AND ZW49 AGREEMENTS AND US$20 MILLION UNDER PLATFORM AGREEMENT.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE DEVELOPMENT AND COMMERCIAL RIGHTS TO ZYMEWORKS' BISPECIFIC CANDIDATES, ZW25 AND ZW49, IN ASIA.ZYMEWORKS INC - BEIGENE ALSO ACQUIRES LICENSES FOR ZYMEWORKS' AZYMETRIC AND EFECT PLATFORMS.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE RIGHTS TO ZW25 AND ZW49, IN ASIA (EXCLUDING JAPAN), AUSTRALIA, AND NEW ZEALAND.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS PLUS POTENTIAL ROYALTIES ON PRODUCT SALES..ZYMEWORKS - IS ELIGIBLE TO RECEIVE UP TO US$390 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR BOTH PRODUCT CANDIDATES.ZYMEWORKS - UNDER TERMS OF AGREEMENT FOR AZYMETRIC AND EFECT PLATFORMS, CO ELIGIBLE TO RECEIVE UP TO AN AGGREGATE OF US$702 MILLION IN MILESTONE PAYMENTS.ZYMEWORKS - ELIGIBLE TO GET UPTO $702 MILLION IN DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS FOR UP TO 3 BISPECIFIC PRODUCT CANDIDATES DEVELOPED.  Full Article

Zymeworks Reports Q3 Loss Per Share Of $0.59
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018.ZYMEWORKS INC - REVENUE FOR THREE MONTHS ENDED SEPTEMBER 30, 2018 WAS $2.1 MILLION AS COMPARED TO $0.1 MILLION.ZYMEWORKS INC - AS OF SEPTEMBER 30, 2018, ZYMEWORKS HAD $150.0 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.ZYMEWORKS INC - QTRLY LOSS PER SHARE $0.59.  Full Article

Zymeworks Inc - QTRLY Loss Per Share $0.83
Tuesday, 1 May 2018 

Zymeworks Inc ::ZYMEWORKS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.ZYMEWORKS INC - REVENUE FOR THREE MONTHS ENDED MARCH 31, 2018 WAS $0.04 MILLION AS COMPARED TO $0.23 MILLION IN SAME PERIOD IN 2017.ZYMEWORKS INC - EXPECTS RESEARCH AND DEVELOPMENT EXPENDITURES TO INCREASE OVER TIME.ZYMEWORKS INC - QTRLY LOSS PER SHARE $0.83.  Full Article

Zymeworks And Celgene Expand Bispecific Antibody Collaboration
Monday, 23 Apr 2018 

April 23 (Reuters) - Celgene Corp ::ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION.ZYMEWORKS INC - CELGENE CORP EXERCISED RIGHT TO EXPAND DEAL FOR COMMERCIALIZATION OF BISPECIFIC ANTIBODY THERAPEUTICS USING CO'S AZYMETRIC PLATFORM.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE AN EXPANSION FEE.ZYMEWORKS INC - IN TOTAL, ZYMEWORKS IS NOW ELIGIBLE TO RECEIVE UP TO $1.64 BILLION IN FUTURE PAYMENTS FOR ENTIRE COLLABORATION.ZYMEWORKS INC - CELGENE HAS EXERCISED ITS RIGHT TO INCREASE NUMBER OF POTENTIAL PRODUCTS IT CAN DEVELOP AND COMMERCIALIZE FROM EIGHT TO TEN.  Full Article

Zymeworks reports third quarter loss of $0.65 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Zymeworks Inc :Zymeworks reports third quarter 2017 financial results and provides business update.Revenues for three months ended September 30, 2017 were $0.1 million compared to $2.2 million for same period of 2016​.Qtrly ‍loss per share $0.65​.  Full Article